Development of Mutant-Selective Allosteric EGFR Inhibitors for Drug-Resistant Lung Cancer is a research paper published in Journal of Pharmacology and Experimental Therapeutics (2023). On theSindex it has a DataRank of 0. It has been cited 1 time.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5P01CA154303-09
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
National Institutes of Health
Grant: 5R35CA242461-04
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
National Institutes of Health
Grant: 5F32CA247198-03
Studies of mutant-selective allosteric inhibitors of EGFR for non-small cell lung cancer
National Institutes of Health
Grant: 2R01CA201049-06
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
FWCI
0.17
Citation Percentile
0.5%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals